AR096161A1 - Derivados de triazina - Google Patents
Derivados de triazinaInfo
- Publication number
- AR096161A1 AR096161A1 ARP140101792A ARP140101792A AR096161A1 AR 096161 A1 AR096161 A1 AR 096161A1 AR P140101792 A ARP140101792 A AR P140101792A AR P140101792 A ARP140101792 A AR P140101792A AR 096161 A1 AR096161 A1 AR 096161A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- represented
- nr5r6
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhibidores de PDE10. Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A, junto con X y el átomo de carbono al que está unido, forma un arilo C₆₋₁₀ o heteroarilo de 5 a 10 miembros, en donde dicha porción arilo o heteroarilo se sustituye opcionalmente con hasta 4 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en cicloalquilo C₃₋₆, oxo, alquilo C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, hidroxi, ciano, halo, -NR⁵R⁶, -C(O)-NR⁵R⁶, -NH-C(O)R⁵, -C(O)-OR⁵, -alquil C₁₋₆-cicloalquilo C₃₋₆, una porción heterocíclica de 4 a 6 miembros, fenilo y bencilo; X es representado por N o C; R¹ está representado por alquilo C₁₋₆, arilo C₆₋₁₀ o una porción heterocíclica de 5 a 6 miembros, en donde dicho alquilo, arilo o porción heterocíclica pueden estar opcionalmente sustituidos con hasta 4 sustituyentes, cada uno independientemente seleccionado del grupo que consiste en halógeno, alquilo C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustituido, hidroxi, ciano, -NR⁵R⁶, -C(O)-NR⁵R⁶, -NH-C(O)R⁵, y -C(O)-OR⁵; R² y R³ son representados, cada uno independientemente, por hidrógeno, alquilo C₁₋₆ opcionalmente sustituido o alcoxi C₁₋₆ opcionalmente sustituido; R⁴, si está presente, es representado opcionalmente con hasta 2 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en fluoro, hidroxi, alquilo C₁₋₆ opcionalmente sustituido o alcoxi C₁₋₆ opcionalmente sustituido, y; R⁵ y R⁶ son representados, cada uno opcional e independientemente, por hidrógeno o alquilo C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818650P | 2013-05-02 | 2013-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096161A1 true AR096161A1 (es) | 2015-12-09 |
Family
ID=50841902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101792A AR096161A1 (es) | 2013-05-02 | 2014-04-30 | Derivados de triazina |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US8933224B2 (es) |
| EP (1) | EP2991989B1 (es) |
| JP (1) | JP6263606B2 (es) |
| KR (1) | KR101770905B1 (es) |
| CN (1) | CN105164134B (es) |
| AP (1) | AP2015008843A0 (es) |
| AR (1) | AR096161A1 (es) |
| AU (1) | AU2014261070A1 (es) |
| BR (1) | BR112015027760A8 (es) |
| CA (1) | CA2910759C (es) |
| CL (1) | CL2015003037A1 (es) |
| CR (1) | CR20150591A (es) |
| CU (1) | CU20150144A7 (es) |
| DK (1) | DK2991989T3 (es) |
| DO (1) | DOP2015000271A (es) |
| EA (1) | EA027936B1 (es) |
| EC (1) | ECSP15050110A (es) |
| ES (1) | ES2637816T3 (es) |
| GE (1) | GEP201706675B (es) |
| HK (1) | HK1213885A1 (es) |
| MA (1) | MA38559B1 (es) |
| MD (1) | MD20150103A2 (es) |
| MX (1) | MX2015015163A (es) |
| NI (1) | NI201500157A (es) |
| NZ (1) | NZ712949A (es) |
| PE (1) | PE20151940A1 (es) |
| PH (1) | PH12015502462A1 (es) |
| SG (1) | SG11201508201VA (es) |
| TN (1) | TN2015000490A1 (es) |
| TW (1) | TWI508966B (es) |
| UA (1) | UA111696C2 (es) |
| UY (1) | UY35547A (es) |
| WO (1) | WO2014177977A1 (es) |
| ZA (1) | ZA201508968B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6263606B2 (ja) * | 2013-05-02 | 2018-01-17 | ファイザー・インク | Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体 |
| CN115215886B (zh) | 2016-09-09 | 2024-10-11 | 诺华股份有限公司 | 作为内体Toll样受体抑制剂的化合物及组合物 |
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| EP4049662A4 (en) | 2019-10-21 | 2023-11-01 | SK Biopharmaceuticals Co., Ltd. | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR THE PREVENTION, RELIEF OR TREATMENT OF COGNITIVE DISORDERS, OR TO IMPROVE COGNITIVE FUNCTION |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| US20070167426A1 (en) | 2004-06-02 | 2007-07-19 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| US8207370B2 (en) | 2006-09-26 | 2012-06-26 | Kaneka Corporation | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| DE102007059723A1 (de) | 2007-12-12 | 2009-06-18 | Siemens Medical Instruments Pte. Ltd. | Hörvorrichtung mit Batterieklappenmodul |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| WO2009117157A1 (en) | 2008-03-20 | 2009-09-24 | Amgen Inc. | Aurora kinase modulators and method of use |
| BR112012010041A2 (pt) * | 2009-10-30 | 2016-05-24 | Janssen Pharmaceutica Nv | derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10 |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| BR112012029994A2 (pt) | 2010-05-28 | 2019-09-24 | Biocryst Pharm Inc | composto heterocíclicos como inibidores de janus quinase |
| JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| BR112013021366A2 (pt) * | 2011-02-23 | 2016-09-13 | Pfizer | imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas |
| JP6263606B2 (ja) * | 2013-05-02 | 2018-01-17 | ファイザー・インク | Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体 |
-
2014
- 2014-04-23 JP JP2016511150A patent/JP6263606B2/ja not_active Expired - Fee Related
- 2014-04-23 WO PCT/IB2014/060945 patent/WO2014177977A1/en active Application Filing
- 2014-04-23 BR BR112015027760A patent/BR112015027760A8/pt not_active Application Discontinuation
- 2014-04-23 KR KR1020157034216A patent/KR101770905B1/ko active IP Right Grant
- 2014-04-23 DK DK14727054.0T patent/DK2991989T3/en active
- 2014-04-23 EP EP14727054.0A patent/EP2991989B1/en active Active
- 2014-04-23 CA CA2910759A patent/CA2910759C/en not_active Expired - Fee Related
- 2014-04-23 ES ES14727054.0T patent/ES2637816T3/es active Active
- 2014-04-23 MX MX2015015163A patent/MX2015015163A/es unknown
- 2014-04-23 MA MA38559A patent/MA38559B1/fr unknown
- 2014-04-23 TN TN2015000490A patent/TN2015000490A1/fr unknown
- 2014-04-23 NZ NZ712949A patent/NZ712949A/en not_active IP Right Cessation
- 2014-04-23 GE GEAP201413979A patent/GEP201706675B/en unknown
- 2014-04-23 MD MDA20150103A patent/MD20150103A2/ro not_active Application Discontinuation
- 2014-04-23 PE PE2015002303A patent/PE20151940A1/es not_active Application Discontinuation
- 2014-04-23 AP AP2015008843A patent/AP2015008843A0/xx unknown
- 2014-04-23 CN CN201480024798.1A patent/CN105164134B/zh not_active Expired - Fee Related
- 2014-04-23 UA UAA201510060A patent/UA111696C2/uk unknown
- 2014-04-23 EA EA201591819A patent/EA027936B1/ru not_active IP Right Cessation
- 2014-04-23 AU AU2014261070A patent/AU2014261070A1/en not_active Abandoned
- 2014-04-23 SG SG11201508201VA patent/SG11201508201VA/en unknown
- 2014-04-29 TW TW103115365A patent/TWI508966B/zh not_active IP Right Cessation
- 2014-04-30 US US14/265,458 patent/US8933224B2/en not_active Expired - Fee Related
- 2014-04-30 UY UY0001035547A patent/UY35547A/es not_active Application Discontinuation
- 2014-04-30 AR ARP140101792A patent/AR096161A1/es unknown
- 2014-11-21 US US14/549,871 patent/US9145427B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/829,842 patent/US9296761B2/en not_active Expired - Fee Related
- 2015-10-13 CL CL2015003037A patent/CL2015003037A1/es unknown
- 2015-10-19 CU CUP2015000144A patent/CU20150144A7/es unknown
- 2015-10-23 PH PH12015502462A patent/PH12015502462A1/en unknown
- 2015-10-27 CR CR20150591A patent/CR20150591A/es unknown
- 2015-10-30 NI NI201500157A patent/NI201500157A/es unknown
- 2015-11-02 DO DO2015000271A patent/DOP2015000271A/es unknown
- 2015-11-30 EC ECIEPI201550110A patent/ECSP15050110A/es unknown
- 2015-12-01 ZA ZA2015/08968A patent/ZA201508968B/en unknown
-
2016
- 2016-02-18 HK HK16101771.5A patent/HK1213885A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR110405A1 (es) | Compuestos | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR109349A1 (es) | Compuestos y usos | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR094712A1 (es) | Modificador de sabor dulce | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR104262A1 (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |